Core Viewpoint - China Construction Bank has obtained a patent for a mobile payment method and device based on electronic certificates, indicating its commitment to innovation in financial technology [1]. Company Overview - China Construction Bank Corporation was established in 2004 and is located in Beijing, primarily engaged in monetary financial services [1]. - The registered capital of China Construction Bank is approximately 26.16 billion RMB [1]. Investment and Business Activities - The company has invested in 37 enterprises and participated in 44,982 bidding projects [1]. - China Construction Bank holds 1,895 trademark registrations and 5,000 patent records, showcasing its extensive intellectual property portfolio [1]. - The bank has obtained 149 administrative licenses, reflecting its compliance and operational capabilities [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感 染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。 格隆汇3月17日丨上海医药(601607.SH)公布，公司下属上海上药新亚药业有限公司（称"上药新亚"）的 注射用头孢唑林钠（称"该药品"）收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知 书编号：2026B01286、2026B01287），该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Core Viewpoint - China CRRC's stock price decreased by 0.47% on March 17, with a trading volume of 824 million yuan and a market capitalization of 183.099 billion yuan [1][11]. Group 1: Company Overview - China CRRC Corporation Limited is located in Haidian District, Beijing, established on December 28, 2007, and listed on August 18, 2008. The company primarily engages in the research, manufacturing, sales, repair, and leasing of railway locomotives, passenger cars, EMUs, urban rail vehicles, and key components [8]. - The revenue composition of China CRRC includes: railway equipment 49.86%, new industries 34.01%, urban rail and infrastructure 14.53%, and modern services 1.60% [8]. - As of September 30, 2025, the number of shareholders is 498,200, a decrease of 2.91% from the previous period, with an average of 49,029 circulating shares per shareholder, an increase of 3.01% [8]. Group 2: Financial Performance - For the period from January to September 2025, China CRRC achieved a revenue of 183.865 billion yuan, representing a year-on-year growth of 20.50%. The net profit attributable to shareholders was 9.964 billion yuan, with a year-on-year increase of 37.53% [8]. - China CRRC has distributed a total of 63.599 billion yuan in dividends since its A-share listing, with 20.663 billion yuan distributed over the past three years [9]. Group 3: Shareholding and Institutional Holdings - Among the top ten circulating shareholders, China Securities Finance Corporation holds 606 million shares, remaining unchanged from the previous period, while Hong Kong Central Clearing Limited holds 442 million shares, a decrease of 400 million shares from the previous period [19]. - The company is classified as a "state-owned enterprise" with its actual controller being the State-owned Assets Supervision and Administration Commission or central state-owned enterprises [3][12]. Group 4: Market Activity and Technical Analysis - The main capital flow showed a net outflow of 37.741 million yuan today, accounting for 0.05%, with the industry ranking at 30 out of 33, indicating a continuous reduction in main capital over three days [4][14]. - The average trading cost of the stock is 6.93 yuan, with the current stock price fluctuating between resistance at 6.47 yuan and support at 6.25 yuan, suggesting potential for range trading [7][17].

3月17日，赣锋锂业跌2.99%，成交额21.49亿元，换手率2.55%，总市值1436.03亿元。 异动分析 盐湖提锂+金属钴+小金属概念+锂电池概念+特斯拉概念 1、公司持有的阿根廷Cauchari-Olaroz项目的含锂卤水资源量为约合2,458万吨LCE，是目前全球最大的 盐湖提锂项目之一，支持年产量超过4万吨电池级碳酸锂并持续40年。 2、2020年6月29日公告显示：公司以自有资金 30,011.7 万元人民币在江西省产权交易所成功竞得新余高 新投资有限公司持有的赣州腾远钴业新材料股份有限公司6,514,553 股份，本次交易完成后，公司将持 有腾远钴业 6.8966%的股权。 3、2020年6月29日公告显示：公司以自有资金 30,011.7 万元人民币在江西省产权交易所成功竞得新余高 新投资有限公司持有的赣州腾远钴业新材料股份有限公司6,514,553 股份，本次交易完成后，公司将持 有腾远钴业 6.8966%的股权。 4、江西赣锋锂业集团股份有限公司的主营业务是从磷酸铁锂蓄电池废物（我们最具代表性的回收产品 之一）回收硫酸锂溶液的回收流程公司的主要产品是氢氧化锂、碳酸锂、金属锂、固体电解质材 ...

3月17日，招商证券涨1.01%，成交额9.70亿元，换手率0.81%，总市值1395.79亿元。 异动分析 证金持股+国企改革+央企国企改革 1、公司前十大流通股东中包含中央汇金资产管理有限责任公司或中国证券金融股份有限公司。 2、公司属于国有企业。公司的最终控制人为国务院国有资产监督管理委员会。 3、公司最终控制人为国务院国有资产监督管理委员会 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入3515.93万，占比0.04%，行业排名19/50，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入29.75亿，当前无连续增减仓现象，主力趋势不明显。 | 区间 | 今日 | 近3日 | 近5日 | 近10日 | 近20日 | | --- | --- | --- | --- | --- | --- | | 主力净流入 | 3398.77万 | 2246.84万 | -76.27万 | -1.18亿 | -7.48亿 | 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.18亿，占总成交额的1.08%。 技术面：筹码平均交易成本为17.0 ...

3月17日，福耀玻璃涨0.31%，成交额10.74亿元，换手率0.90%，总市值1543.14亿元。 异动分析 证金持股+特斯拉概念+光伏概念 1、公司前十大流通股东中包含中央汇金资产管理有限责任公司或中国证券金融股份有限公司。 2、2019年9月2日公司在互动平台称：公司有为小鹏、蔚来、威马等新能源汽车提供汽车玻璃产品，此 外，公司亦为上海特斯拉的汽车玻璃供应商。 3、公司位于美国的全资子公司福耀玻璃伊利诺伊有限公司有生产光伏组件背板玻璃，公司具备背板玻 璃的生产技术，公司计划将进一步扩大国内外光伏玻璃市场。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-188.42万，占比0%，行业排名136/264，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入3.85亿，当前无连续增减仓现象，主力趋势不明显。 | 区间 | 今日 | 近3日 | 近5日 | 近10日 | 近20日 | | --- | --- | --- | --- | --- | --- | | 主力净流入 | 535.74万 | 7636.51万 | 1.96亿 | 2. ...

"清仓"离场与"猴价"上涨 根据昭衍新药3月17日发布的公告，顾晓磊及其一致行动人顾美芳目前分别持有公司A股股份2042.05万 股、1032.2万股，持股比例分别约为2.73%、1.38%。股东顾晓磊及其一致行动人顾美芳拟自减持计划公 告之日起3个交易日后的3个月内，通过上交所以集中竞价的方式分别减持2042.05万股、1032.2万股，合 计减持3074.25万股，占公司当前总股本的4.1%。 继前一日发布股东减持计划公告后，昭衍新药今日开盘即跳空低开，盘中一度重挫逾9%，截至发稿时 股价仍徘徊在底部区域，市场恐慌情绪可见一斑。引发此次股价地震的，是一则"清仓式"减持公告：公 司股东顾晓磊及其一致行动人顾美芳拟在未来三个月内，通过集中竞价方式合计减持所持有的全部 3074.25万股A股，占公司总股本的4.1%。 不过，就在不到两个月前，昭衍新药刚刚交出了一份看似靓丽的2025年业绩预告：归母净利润同比暴增 逾两倍。一边是业绩的爆发式增长，另一边却是两股东"清仓式"减持连夜离场。这背后究竟隐藏着怎样 的逻辑？在CRO行业整体景气度回春的当下，"猴茅"昭衍新药为何留不住人？ 对此，有券商医药行业分析师对21世 ...

Group 1 - The core point of the article is that China Construction Bank has obtained a patent for a method and device related to business demand matching, indicating its focus on innovation and technology development [1] Group 2 - China Construction Bank was established in 2004 and is headquartered in Beijing, primarily engaged in monetary financial services [1] - The registered capital of China Construction Bank is approximately 26.16 billion RMB [1] - The bank has made investments in 37 companies and participated in 44,983 bidding projects [1] - China Construction Bank holds 1,895 trademark registrations and 5,000 patent records, along with 149 administrative licenses [1]